Commences phase III trials
Cadila Healthcare announced that the Zydus Group has initiated the phase III trials of its breakthrough drug Lipaglyn (Saroglitazar) for patients suffering from lipodystrophy.The drug is already approved in India for treating diabetic dyslipidemia and hypertriglyceridemia.
The goal of the trial is to evaluate the safety and efficacy of Lipaglyn 4mg versus standard-of-care with placebo in the treatment of lipodystrophy.
Powered by Capital Market - Live News
